Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.

Ítems similars

• Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.
  per: Sharma, S D, et al.
  Publicat: (1991)
• Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis.
  per: Hood, L, et al.
  Publicat: (1991)
• Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis.
  per: Kumar, V, et al.
  Publicat: (1990)
• LINKAGE OF SUSCEPTIBILITY TO EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS TO THE MAJOR HISTOCOMPATIBILITY LOCUS IN THE RAT
  per: Williams, R. Michael, et al.
  Publicat: (1973)
• Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide
  Publicat: (1993)